A Phase 4 interventional study of Calcitonin Gene-Related Peptide and Erenumab in Migraine, sponsored by Danish Headache Center. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-10-24.
Sponsored by Danish Headache Center · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing erenumab in Migraine Disorders — 3 open to participants now, 4 under way, 1 of them phase 3. erenumab · Migraine Disorders.
Among the 37 studies testing erenumab in Migraine Disorders, this one is the 17th largest by planned enrollment, is one of 7 that started in 2020, is one of 16 in phase 4, and was the 31st registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →3 of the 37 studies testing erenumab in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:
Danish Headache Center · Sites in Denmark
Ages 18+
Stanford University
Ages 18+
By country, each count listing its studies:
erenumab: first FDA approval 2018 (AIMOVIG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 7 started in 2020.
This study's planned enrollment of 400 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 261 across the 37 interventional studies. Of the 29 that completed or were terminated, 28 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 37 have an industry lead sponsor. The 8 most frequent:
Danish Headache Center is the lead sponsor of 129 studies on the registry; 15 are open to participants now.
57 studies in Migraine Disorders by Danish Headache Center: 9 open now, 10 under way, none of them phase 3. Of 40 finished, 0 (0%) have results posted.
Among the 57 studies in Migraine Disorders by Danish Headache Center, this one is the 2nd largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2020, is one of 3 in phase 4, and was the 40th registered.
Danish Headache Center’s Migraine Disorders studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing erenumab in Migraine Disorders, from their registry updates:
Among Danish Headache Center’s 57 in Migraine Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To explore the relationship between clinical response to erenumab and response to intravenous infusion of calcitonin gene-related peptide in individuals with migraine.
This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Provocation Phase: Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes. Open-Label Treatment Phase: Erenumab packed in a SureClick® Autoinjector Pen (AI)
Drug: Calcitonin Gene-Related Peptide · Drug: Erenumab
Intravenous infusion of 1.5 µg/min of calcitonin-gene related peptide over 20 minutes.
Also known as: CGRP
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Also known as: Aimovig
Headache Diary (Baseline Phase and Treatment Phase)
Headache diary with daily entries to record migraine-related data (e.g. migraine days, headache days, number of days with use of acute migraine medication, number of days with aura).
Time frame: Baseline Phase (Day -28 to Day 1) to Week 24
Headache Diary (Provocation Phase)
Subjects will be instructed to fill out a headache diary during the 12-hour observational period. The diary will be used to record migraine-related data (e.g. location, quality, intensity, aggravation by routine physical activity, use of acute migraine medication, nausea, vomiting, photophobia, and phonophobia)
Time frame: Provocation Phase (12 Hours)
Semi-Structured Interview
In-person semi-structured interview to record migraine-related data (e.g. location, quality, intensity, aggravation by routine physical activity, use of acute migraine medication, nausea, vomiting, photophobia, phonophobia, premonitory symptoms, postdromal symptoms, trigger factors, autonomic symptoms).
Time frame: 1 Hour
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Aug 2025, 57 months after the start.
Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 57 months is above that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcitonin Gene-Related Peptide · Erenumab